Dublin, March 14, 2024 (GLOBE NEWSWIRE) — The “Global Nanotechnology Drug Delivery Market Size, Share & Trends Analysis Report By Formulation (Polymer-Based Nanomedicine, Lipid-Based Nanomedicine, Nanocrystals, and Others), By Application, By Regional Outlook and Forecast, 2023 – 2030” report has been added to ResearchAndMarkets.com’s offering.
This comprehensive research on the Global Nanotechnology Drug Delivery Market delivers a detailed analysis of the industry’s anticipated growth trajectory, with a robust focus on formulation types and applications. The study projects that this sector is poised to amass $153 billion in revenue by 2030, expanding with a CAGR of 8.7% during the forecast period.
The research highlights the remarkable strides made within the neurology segment, where the market earned revenues of $6.76 billion in 2022. The application of nanotechnology in neurology has dramatically improved drug stability against enzymatic degradation and ensured sustained release. Such advancements are especially significant in managing chronic diseases requiring continuous treatment.
Key Insights and Growth Prospects in Nanotechnology Drug Delivery
- The increased efficiency in drug loading and greater bioavailability of hydrophobic drugs through nanoparticle encapsulation signal growth opportunities for market stakeholders.
- Targeted delivery employing nanoparticles can reduce side effects and enhance precision in treatment, especially crucial within fields such as oncology.
Despite the initial setbacks presented by the COVID-19 pandemic, the market saw moderate impacts. The pandemic highlighted the versatile applications of nanoparticles, from antiviral coatings to enhancing diagnostic tests.
However, the complexities associated with nanoscale drug delivery systems, such as their design, synthesis, and characterization, present restraints due to the specialized knowledge and facilities required.
Market Dynamics Shaped by Varied Applications
The oncology and hematology segment of the market commanded the highest revenue share owing to the pressing need for targeted drug delivery mechanisms in the treatment of hematological disorders. Similarly, the lipid-based nanomedicine segment noted a notable revenue share, attributed to the biocompatibility of lipid-based nanocarriers, which are seen as key to future market expansion.
Regional Performance and Key Market Players
North America’s Leadership: The region retains the dominant position, bolstered by its strong research infrastructure and innovation landscape.
- Oncology & Hematology
- Infectious Diseases
- Orthopedics
- Neurology
- Immunology
- Urology
- Others
The report profiles prominent market players who are pivotal to the sector’s advancement, including leading pharmaceutical and biotech companies recognized for their contributions to nanotechnology drug delivery advancements.
By offering a granular analysis of regional performance, the study underlines the substantive growth in the North American market, alongside an assessment of markets across Europe, Asia Pacific, and LAMEA.
This research provides in-depth sectoral insights, highlighting technological breakthroughs, market dynamics, and emerging trends that will shape the Global Nanotechnology Drug Delivery Industry in the coming decade.
Companies Mentioned
- AbbVie, Inc.
- Pfizer Inc.
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Novartis AG
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Amgen, Inc.
- Merck KGaA
- Teva Pharmaceutical Industries Ltd.
- Sanofi SA
For more information about this report visit https://www.researchandmarkets.com/r/ou70z3
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- nanotechnology-drug-delivery-market-size.jpg
- nanotechnology-drug-delivery-market-share.jpg
